

## MULTIPLE SCLEROSIS

Study	Title	Description	Link to ClinicalTrials.Gov
COMB157G23101	An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumab	The purpose of the study is to complement the ofatumumab pivotal Phase 3 program by exploring outcomes of patients transitioning from commonly used oral therapies, dimethyl fumarate (DMF) or fingolimod, to ofatumumab due to breakthrough disease (defined as relapse, Gd+, or new/enlarging T2 lesions)	<a href="https://clinicaltrials.gov/ct2/show/NCT04353492?term=COMB157G23101&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT04353492?term=COMB157G23101&amp;draw=2&amp;rank=1</a>